DEVELOPMENT AND TESTING OF CIRCULATING-FREE METHYLATION DNA AS A PROGNOSTIC BIOMARKER FOR RECURRENT KIDNEY CANCER...NEW GRANT, SIGNED ON 8/27/2019, DISTRIBUTED ON 8/27/2019, FAADC ON 8/28/2019
$454,701FY2019Department of the ArmyDOD
Dana-Farber Cancer Institute, Inc.